Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication

Min Hyuk Yoo, Xue Ming Xu, Bradley A. Carlson, Andrew David Patterson, Vadim N. Gladyshev, Dolph L. Hatfield

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Thioredoxin reductase 1 (TR1) is a major redox regulator in mammalian cells. As an important antioxidant selenoprotein, TR1 is thought to participate in cancer prevention, but is also known to be over-expressed in many cancer cells. Numerous cancer drugs inhibit TR1, and this protein has been proposed as a target for cancer therapy. We previously reported that reduction of TR1 levels in cancer cells reversed many malignant characteristics suggesting that deficiency in TR1 function is antitumorigenic. The molecular basis for TR1's role in cancer development, however, is not understood. Herein, we found that, among selenoproteins, TR1 is uniquely overexpressed in cancer cells and its knockdown in a mouse cancer cell line driven by oncogenic k-ras resulted in morphological changes characteristic of parental (normal) cells, without significant effect on cell growth under normal growth conditions. When grown in serum-deficient medium, TR1 deficient cancer cells lose self-sufficiency of growth, manifest a defective progression in their S phase and a decreased expression of DNA polymerase α, an enzyme important in DNA replication. These observations provide evidence that TR1 is critical for self-sufficiency in growth signals of malignant cells, that TR1 acts largely as a pro-cancer protein and it is indeed a primary target in cancer therapy.

Original languageEnglish (US)
Article numbere1112
JournalPloS one
Volume2
Issue number10
DOIs
StatePublished - Oct 31 2007

Fingerprint

Thioredoxin Reductase 1
DNA replication
DNA Replication
Cells
neoplasms
DNA
Growth
selenoproteins
Neoplasms
Selenoproteins
therapeutics
DNA-directed DNA polymerase
cells
interphase
neoplasm cells
cell growth
proteins
cell lines
Cell growth
DNA-Directed DNA Polymerase

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Yoo, Min Hyuk ; Xu, Xue Ming ; Carlson, Bradley A. ; Patterson, Andrew David ; Gladyshev, Vadim N. ; Hatfield, Dolph L. / Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. In: PloS one. 2007 ; Vol. 2, No. 10.
@article{690e3f9356524887b766b1699f4cafa3,
title = "Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication",
abstract = "Thioredoxin reductase 1 (TR1) is a major redox regulator in mammalian cells. As an important antioxidant selenoprotein, TR1 is thought to participate in cancer prevention, but is also known to be over-expressed in many cancer cells. Numerous cancer drugs inhibit TR1, and this protein has been proposed as a target for cancer therapy. We previously reported that reduction of TR1 levels in cancer cells reversed many malignant characteristics suggesting that deficiency in TR1 function is antitumorigenic. The molecular basis for TR1's role in cancer development, however, is not understood. Herein, we found that, among selenoproteins, TR1 is uniquely overexpressed in cancer cells and its knockdown in a mouse cancer cell line driven by oncogenic k-ras resulted in morphological changes characteristic of parental (normal) cells, without significant effect on cell growth under normal growth conditions. When grown in serum-deficient medium, TR1 deficient cancer cells lose self-sufficiency of growth, manifest a defective progression in their S phase and a decreased expression of DNA polymerase α, an enzyme important in DNA replication. These observations provide evidence that TR1 is critical for self-sufficiency in growth signals of malignant cells, that TR1 acts largely as a pro-cancer protein and it is indeed a primary target in cancer therapy.",
author = "Yoo, {Min Hyuk} and Xu, {Xue Ming} and Carlson, {Bradley A.} and Patterson, {Andrew David} and Gladyshev, {Vadim N.} and Hatfield, {Dolph L.}",
year = "2007",
month = "10",
day = "31",
doi = "10.1371/journal.pone.0001112",
language = "English (US)",
volume = "2",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. / Yoo, Min Hyuk; Xu, Xue Ming; Carlson, Bradley A.; Patterson, Andrew David; Gladyshev, Vadim N.; Hatfield, Dolph L.

In: PloS one, Vol. 2, No. 10, e1112, 31.10.2007.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication

AU - Yoo, Min Hyuk

AU - Xu, Xue Ming

AU - Carlson, Bradley A.

AU - Patterson, Andrew David

AU - Gladyshev, Vadim N.

AU - Hatfield, Dolph L.

PY - 2007/10/31

Y1 - 2007/10/31

N2 - Thioredoxin reductase 1 (TR1) is a major redox regulator in mammalian cells. As an important antioxidant selenoprotein, TR1 is thought to participate in cancer prevention, but is also known to be over-expressed in many cancer cells. Numerous cancer drugs inhibit TR1, and this protein has been proposed as a target for cancer therapy. We previously reported that reduction of TR1 levels in cancer cells reversed many malignant characteristics suggesting that deficiency in TR1 function is antitumorigenic. The molecular basis for TR1's role in cancer development, however, is not understood. Herein, we found that, among selenoproteins, TR1 is uniquely overexpressed in cancer cells and its knockdown in a mouse cancer cell line driven by oncogenic k-ras resulted in morphological changes characteristic of parental (normal) cells, without significant effect on cell growth under normal growth conditions. When grown in serum-deficient medium, TR1 deficient cancer cells lose self-sufficiency of growth, manifest a defective progression in their S phase and a decreased expression of DNA polymerase α, an enzyme important in DNA replication. These observations provide evidence that TR1 is critical for self-sufficiency in growth signals of malignant cells, that TR1 acts largely as a pro-cancer protein and it is indeed a primary target in cancer therapy.

AB - Thioredoxin reductase 1 (TR1) is a major redox regulator in mammalian cells. As an important antioxidant selenoprotein, TR1 is thought to participate in cancer prevention, but is also known to be over-expressed in many cancer cells. Numerous cancer drugs inhibit TR1, and this protein has been proposed as a target for cancer therapy. We previously reported that reduction of TR1 levels in cancer cells reversed many malignant characteristics suggesting that deficiency in TR1 function is antitumorigenic. The molecular basis for TR1's role in cancer development, however, is not understood. Herein, we found that, among selenoproteins, TR1 is uniquely overexpressed in cancer cells and its knockdown in a mouse cancer cell line driven by oncogenic k-ras resulted in morphological changes characteristic of parental (normal) cells, without significant effect on cell growth under normal growth conditions. When grown in serum-deficient medium, TR1 deficient cancer cells lose self-sufficiency of growth, manifest a defective progression in their S phase and a decreased expression of DNA polymerase α, an enzyme important in DNA replication. These observations provide evidence that TR1 is critical for self-sufficiency in growth signals of malignant cells, that TR1 acts largely as a pro-cancer protein and it is indeed a primary target in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=39749177838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749177838&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0001112

DO - 10.1371/journal.pone.0001112

M3 - Article

VL - 2

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e1112

ER -